Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy Ganji Purnachandra Nagaraju

Format:

Book

Author/Creator:

Nagaraju, Ganji Purnachandra, author.

Series:

Cancer sensitizing agents for chemotherapy v. 5

Cancer sensitizing agents for chemotherapy volume 5

Language:

English

Subjects (All):

Pancreas--Cancer.

Pancreas.

Chemotherapy.

Drug resistance in cancer cells.

Drug Resistance, Neoplasm.

Pancreatic Neoplasms--drug therapy.

Drug Therapy.

Pancreatic Neoplasms.

Medical Subjects:

Drug Resistance, Neoplasm.

Pancreatic Neoplasms--drug therapy.

Drug Therapy.

Pancreatic Neoplasms.

Genre:

Internet Resources

Physical Description:

1 online resource

Edition:

First edition

Place of Publication:

London Academic Press [2019]

System Details:

text file

Contents:

Front Cover; Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy; Copyright; Dedication; Contents; Contributors; About the Editor; About the Series Editor; Aims and Scope for Series ""Cancer Sensitizing Agents for Chemotherapy; Preface; Chapter 1: Overview of Pancreatic Cancer Biology; Introduction; Pathogenesis and Molecular Biology; Three Biological Stages of Cancer Development; Initiation; Clonal Expansion; Oncogenesis; KRAS; Raf/Mitogen-Activated Protein Kinase (MAPK) Cascade; Phosphoinositide 3-Kinase/ATK Cascade; Nuclear Factor Kappa B Signaling Cascade

Tumor Suppressor GenesCDKN2A; TP53; SMAD4; Introduction to Local and Distant Microenvironments; Familial Pancreatic Cancers; Conclusions; References; Further Reading; Chapter 2: Chemoresistance in Pancreatic Cancer: Emphasis on Age and Gender; Introduction; Pancreatic Cancer Incidences and Prognosis: Association of Age and Gender; Chemoresistance: Association With Age and Gender; Mechanisms Associated With Chemoresistance; Factors Modulated in Various Age Groups; Conclusion; Acknowledgments; References; Chapter 3: EMT Contributes to Chemoresistance in Pancreatic Cancer; Introduction

Gemcitabine SensitivityGemcitabine and Chemoresistance; Role of Gemcitabine in Targeting Signaling Pathways; Conclusion; Acknowledgment; References; Chapter 5: Pancreatic Cancer and Possible Therapeutic Options; Introduction; Reasons Behind the Above Statistics?; Brief Outline of Treatment; Tumor-Node-Metastasis Staging and Clinical Classification; Modalities for Evaluating TNM Staging; Clinical Classification; Treatment Options for Pancreatic Adenocarcinoma; Localized Surgically Resectable Stage I and II Disease; Adjuvant Therapy; Gemcitabine and 5-Fluorouracil; Gemcitabine and S-1

Gemcitabine and CapecitabineAdjuvant Chemoradiation; Gemcitabine Plus Nab-Paclitaxel; Neoadjuvant Therapy; Adjuvant Therapy in Borderline Removable Pancreatic Carcinoma; Evidence Supporting Neoadjuvant Therapy; FOLFIRINOX as Neoadjuvant Therapy; NAC-GSL (Neoadjuvant Chemotherapy-Gemcitabine, S-1, LV); Metastatic Pancreatic Cancer: Treatment Options; Early Period; First-Line Therapies; FOLFIRINOX; PRODIGE-4/ACCORD-11 Trial; Outcomes of PRODIGE-4/ACCORD-11 Trial; Precautionary and Toxicity Reducing Strategies; Gemcitabine Plus Nab-Paclitaxel; The MPACT Trial

Pancreatic Cancer MetastasisEMT Regulation in Pancreatic Cancers; ZEB1; SNAIL; Twist; PRRX1 (Paired Related Homeobox 1); Signaling Pathways Involved in the Regulation of EMT; TGF-β; Wnt/β-catenin; Notch; TNF-α; EMT in Chemoresistance in Pancreatic Cancer; 5-Flurouracil Chemoresistance; Gemcitabine Chemoresistance; Role of EMT in Gemcitabine Resistance; Promising Ways to Improving Gemcitabine Efficacy; Conclusions and Future Perspectives; Acknowledgments; References; Chapter 4: Pancreatic Cancer Resistance to Gemcitabine; Introduction; Gemcitabine Structure and Mechanism

Notes:

Includes bibliographical references and index

Online resource; title from PDF title page (EBSCO, viewed March 4, 2019)

Other Format:

Print version Nagaraju, Ganji Purnachandra. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy.

ISBN:

9780128176627

0128176628

OCLC:

1088892218

Access Restriction:

Restricted for use by site license